Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Get Free Report) were down 4.2% during mid-day trading on Wednesday . The company traded as low as $21.84 and last traded at $21.85. Approximately 211,684 shares changed hands during trading, a decline of 80% from the average daily volume of 1,042,027 shares. The stock had previously closed at $22.81.
Wall Street Analyst Weigh In
A number of equities analysts have recently issued reports on EYPT shares. JPMorgan Chase & Co. started coverage on shares of EyePoint Pharmaceuticals in a research report on Monday, January 22nd. They set an “overweight” rating and a $35.00 target price on the stock. Mizuho upped their target price on shares of EyePoint Pharmaceuticals from $30.00 to $39.00 and gave the stock a “buy” rating in a research report on Friday, February 16th. HC Wainwright reduced their target price on shares of EyePoint Pharmaceuticals from $35.00 to $33.00 and set a “buy” rating on the stock in a research report on Tuesday, January 16th. Finally, Capital One Financial reissued an “overweight” rating on shares of EyePoint Pharmaceuticals in a research note on Friday, February 16th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, EyePoint Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $33.86.
EyePoint Pharmaceuticals Price Performance
The stock has a market cap of $1.10 billion, a P/E ratio of -12.04 and a beta of 1.66. The company’s 50 day simple moving average is $25.54 and its 200 day simple moving average is $16.19.
EyePoint Pharmaceuticals (NASDAQ:EYPT – Get Free Report) last issued its earnings results on Thursday, March 7th. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.60) by $0.27. EyePoint Pharmaceuticals had a negative net margin of 153.84% and a negative return on equity of 61.48%. The firm had revenue of $14.03 million during the quarter, compared to the consensus estimate of $8.71 million. During the same quarter in the prior year, the firm earned ($0.61) earnings per share. On average, equities research analysts predict that EyePoint Pharmaceuticals, Inc. will post -1.8 earnings per share for the current year.
Insider Buying and Selling at EyePoint Pharmaceuticals
In other EyePoint Pharmaceuticals news, insider Dario A. Paggiarino sold 22,913 shares of the company’s stock in a transaction that occurred on Monday, January 8th. The shares were sold at an average price of $21.13, for a total value of $484,151.69. Following the completion of the sale, the insider now owns 36,505 shares of the company’s stock, valued at $771,350.65. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, insider Dario A. Paggiarino sold 22,913 shares of the stock in a transaction on Monday, January 8th. The shares were sold at an average price of $21.13, for a total transaction of $484,151.69. Following the completion of the sale, the insider now owns 36,505 shares of the company’s stock, valued at $771,350.65. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Ye Liu sold 1,910,500 shares of the stock in a transaction on Thursday, January 11th. The stock was sold at an average price of $19.45, for a total transaction of $37,159,225.00. Following the sale, the director now directly owns 100,221 shares of the company’s stock, valued at approximately $1,949,298.45. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,989,582 shares of company stock valued at $39,080,886. Corporate insiders own 13.05% of the company’s stock.
Institutional Investors Weigh In On EyePoint Pharmaceuticals
Several large investors have recently made changes to their positions in the stock. Deutsche Bank AG increased its position in shares of EyePoint Pharmaceuticals by 4.0% during the third quarter. Deutsche Bank AG now owns 21,764 shares of the company’s stock worth $174,000 after acquiring an additional 830 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in EyePoint Pharmaceuticals by 6.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 15,584 shares of the company’s stock worth $360,000 after purchasing an additional 882 shares during the last quarter. American International Group Inc. boosted its holdings in EyePoint Pharmaceuticals by 10.2% during the first quarter. American International Group Inc. now owns 12,370 shares of the company’s stock worth $150,000 after purchasing an additional 1,142 shares during the last quarter. FNY Investment Advisers LLC acquired a new position in EyePoint Pharmaceuticals during the fourth quarter worth $27,000. Finally, Tower Research Capital LLC TRC boosted its holdings in EyePoint Pharmaceuticals by 36.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,724 shares of the company’s stock worth $109,000 after purchasing an additional 1,250 shares during the last quarter. Institutional investors own 99.41% of the company’s stock.
EyePoint Pharmaceuticals Company Profile
EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company’s pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.